Skip to main content
European Commission logo
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

AGE-RELATED CHANGES IN HEMATOPOIESIS

Description du projet

L’arrivée de sang nouveau dans la recherche va s’attaquer aux maladies du sang liées au vieillissement

Le sang remplit des fonctions essentielles, notamment en transportant des gaz et des nutriments, en régulant la température et le pH, en assurant la coagulation du sang et la réponse immunitaire. Les dysfonctionnements de l’hématopoïèse (processus par lequel les cellules sanguines se forment) peuvent avoir des effets néfastes à long terme. En vieillissant, ce processus évolue naturellement. Cependant, ces changements peuvent également être associés au développement de maladies hématologiques, notamment l’anémie et certains cancers. Le projet ARCH, financé par l’UE, forme une cohorte de jeunes scientifiques afin d’étudier le lien potentiel entre les modifications du système hématopoïétique liées à l’âge et l’apparition d’une maladie. Leurs contributions devraient avoir un impact sur les résultats pour les patients, le fardeau pesant sur le système de santé et la compétitivité de l’UE dans ce domaine.

Objectif

ARCH is a network of highly qualified experts in experimental hematology created to decipher the causal relationship between the physiological changes in the hematopoietic system during lifespan and the parallel occurrence of specific age-related hematological diseases (pediatric, adult, elderly), with the aim to develop novel targeted therapeutic treatments. ARCH research will integrate the results from complementary model systems (cell lines, mouse models, cells from leukemia patients) and it will deploy a large panel of cutting-edge technologies, such as single cells genomics, epigenomics, genome editing and organoid cultures, in a multi-faceted effort. The ARCH ambitious goal requires scientific and financial resources beyond the capability of a single group. To reach this goal, the ARCH network brings together 15 beneficiaries (12 academic, 2 SMEs and 1 private research institute) and 5 Partner organisations (3 academic, 1 SME and 1 patients’ association). Two European Consortia are present through their italian nodes. ARCH will recruit 15 ESRs that will be all enrolled in PhD programmes. Besides research laboratory work, the ARCH training programme includes scientific, technical and transferable skills courses that will provide ESRs with a solid scientific culture and with awareness of responsible research and innovation issues. This broad portfolio will enable ESRs to become leading academic, clinic or industrial players in the field. The unique combination of scientific excellence, quality of the educational programme and experience in translating basic research into exploitable results will provide ARCH with the real possibility of positively contributing to the enhancement of European competitiveness in the development of innovative, targeted drugs/treatments for hematological diseases, which currently represent a serious socio-economical problem for the European health care system.

Coordinateur

UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA
Contribution nette de l'UE
€ 261 499,68
Adresse
PIAZZA DELL'ATENEO NUOVO 1
20126 MILANO
Italie

Voir sur la carte

Région
Nord-Ovest Lombardia Milano
Type d’activité
Higher or Secondary Education Establishments
Liens
Coût total
€ 261 499,68

Participants (14)

Partenaires (4)